Stay updated on TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial page.

Latest updates to the TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check14 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.8%
- Check21 days agoChange DetectedThe page has removed a detailed citation regarding a clinical trial on trifluridine/tipiracil for metastatic gastric cancer, which was previously included.SummaryDifference0.2%
- Check29 days agoNo Change Detected
- Check43 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check57 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed descriptions of a clinical trial for Refractory Metastatic Gastric Cancer and the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference8%
- Check65 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
Stay in the know with updates to TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial page.